IQVIA (IQV) valuation
IQVIA P/E ratio history
IQVIA trades at 32.6 times its earnings over the last twelve months and 19.2 times the earnings analysts expect over the next twelve. At its last 9 fiscal year ends its P/E ranged from 16.6 (year to Dec 2017) to 159.3 (year to Dec 2019), with a median of 35.8.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $225.41 | $7.84 | 28.8 | 17.8 |
| Dec 31, 2024 | $196.51 | $7.49 | 26.2 | 16.6 |
| Dec 31, 2023 | $231.38 | $7.29 | 31.7 | 21.4 |
| Dec 31, 2022 | $204.89 | $5.72 | 35.8 | — |
| Dec 31, 2021 | $282.14 | $4.95 | 57.0 | 28.7 |
| Dec 31, 2020 | $179.17 | $1.43 | 125.3 | — |
| Dec 31, 2019 | $154.51 | $0.97 | 159.3 | — |
| Dec 31, 2018 | $116.17 | $1.24 | 93.7 | — |
| Dec 31, 2017 | $97.90 | $5.90 | 16.6 | — |
| Dec 31, 2016 | $76.05 | — | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
IQVIA valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| IQVIAIQV | $44.0B | 32.6 | 19.2 | 2.5 |
| WatersWAT | $45.4B | 115.4 | 29.7 | 9.8 |
| Agilent TechnologiesA | $49.4B | 34.4 | 26.5 | 6.7 |
| Mettler ToledoMTD | $33.8B | 37.8 | 33.8 | 8.2 |
| Charles River LaboratoriesCRL | $17.3B | — | 29.8 | 4.3 |
| Bio-TechneTECH | $11.4B | 62.6 | 35.7 | 9.4 |
| Peer median | 50.2 | 29.8 | 8.2 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: IQV financials · IQV returns
No forecast, no recommendation. This page describes IQVIA from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.